LabGenomics Co., Ltd.
Financials
Valuation Metrics
LabGenomics Co., Ltd.'s Market Cap is ₩282B. At end of 2025 it was ₩1344B. Ranked #2069 of 2,405 in KR market (top 86%), #1323 of 1,627 on KOSDAQ (top 81%), #215 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 28.24B KRW | KR#2,069/2,405 Sec#215/231 |
| Revenue | 77.64B KRW | KR#1,560/2,405 Sec#99/231 |
| Net Income | -51.60B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 232.08B KRW | KR#1,204/2,405 Sec#85/231 |
| Net Assets | 147.96B KRW | KR#1,143/2,405 Sec#80/231 |
| Employees | 186 | KR#1,147/2,405 Sec#96/231 |
| Value | ||
| P/B | 0.19x | KR#140/2,405 Sec#7/231 |
| P/S | 0.36x | KR#757/2,405 Sec#23/231 |
| FCF Yield | -112.16% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -34.87% | KR#2,206/2,405 Sec#186/231 |
| ROA | -22.23% | KR#2,249/2,405 Sec#181/231 |
| Op. Margin | -49.82% | KR#2,221/2,405 Sec#161/231 |
| Revenue Growth | -11.73% | KR#1,954/2,405 Sec#180/231 |
| Financial Health | ||
| Debt Ratio | 56.85% | KR#1,050/2,405 Sec#122/231 |
| FCF | -31.67B KRW | KR#1,992/2,405 Sec#193/231 |
| Cash | 9.35B KRW | KR#1,727/2,405 Sec#147/231 |
| Current Ratio | 1.00x | KR#1,716/2,405 Sec#173/231 |
| Performance | ||
| 1Y Return | -82.75% | KR#2,361/2,405 Sec#229/231 |
| 1M Return | -28.36% | KR#2,196/2,405 Sec#218/231 |
| From 52W High | -85.05% | KR#2,356/2,405 Sec#223/231 |
| 1Y MDD | -86.99% | KR#2,367/2,405 Sec#223/231 |
| Trading | ||
| Volume | 84,878 shares | KR#699/2,405 Sec#75/231 |
| Trading Value | 160.7M KRW | KR#1,222/2,405 Sec#138/231 |
| Foreign Own. | 1.54% | KR#1,806/2,405 Sec#178/231 |
| Per Share | ||
| EPS | -3,475 KRW | KR—/2,405 Sec—/231 |
| BPS | 9,965 KRW | KR#1,004/2,405 Sec#70/231 |
Company Info
Labgenomics, established in 2002 as a specialized genomics molecular diagnostics company and headquartered in Seongnam-si, Gyeonggi-do, was listed on KOSDAQ in 2014. In 2024, the company officially entered the American diagnostic market by acquiring U.S. CLIA labs QDx Pathology Services and IMD, securing a diagnostic service network across the United States. It operates various genomics molecular diagnostics businesses, having commercialized Korea's first Next-Generation Sequencing (NGS)-based non-invasive prenatal testing for fetal abnormalities and established a network of over 3,000 hospitals nationwide.